Viking Therapeutics, Inc. (VKTX) SEC Filings & Earnings Calls
EquiReason read 9 Viking Therapeutics, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-09-28 — Viking Therapeutics completed equity and debt offerings: 2.00% Convertible Senior Notes due 2032; underwriting agreements with Morgan Stanley and J.P. Morgan..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 2.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 28 Oct, in 4 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
28 Sep 20268-K · 1.01, 2.03Viking Therapeutics completed equity and debt offerings: 2.00% Convertible Senior Notes due 2032; underwriting agreements with Morgan Stanley and J.P. Morgan.open
Risks flagged
Dilution risk from convertible notes; debt service obligation
“Convertible Senior Notes due 2032; potential equity dilution upon conversion”
22 Sep 20268-K · 8.01Viking Therapeutics announced top-line results from maintenance study of GLP-1/GIP agonist VK2735. Positive results expected based on prior clinical data. Filing does not include specific data but references 'top-line results' from a mainteopen
Risks flagged
Clinical trial results not detailed in filing; full data disclosure needed to assess magnitude
“Filing references press release with top-line results but does not include specific data points.”
29 Jul 202610-QLigand initiated license termination for TR-Beta Program; VKTX filed cross-complaint.open
Figures in the filing · each found in the filing text
| Accumulated deficit · Q2-2026 | $1.13B | |
| Cash, cash equivalents, short-term investments and restricted cash · Q2-2026 | $502M |
Risks flagged
License termination risk
“On April 24, 2026, Ligand notified us that Ligand is purporting to terminate Ligand’s license of the TR-Beta Program to us under the Master License Agreement. The TR-Beta Program includes our VK2809 and VK0214 product candidates.” · word for word
No revenue / pre-commercial
“We have not yet demonstrated an ability to obtain marketing approval for any of our drug candidates... We also have not generated any revenue to date.” · word for word
29 Jul 20268-K · 2.02Cash and investments $502Mearningsopen
Figures in the filing · each found in the filing text
| Cash and investments · Q2-2026 | $502M |
Risks flagged
Clinical trial failure risk for VK2735 and VK3019; regulatory approval uncertainty.
“Phase 3 trials are ongoing; no efficacy or safety data reported yet.”
30 Apr 202610-QNet loss $-158M; Research and development expense $150M; General and administrative expense $14Mopen
Figures in the filing · each found in the filing text
| Net loss · Q1-2026 | $-158M | |
| Research and development expense · Q1-2026 | $150M | |
| General and administrative expense · Q1-2026 | $14M | |
| Cash and cash equivalents · 2026-03-31 | $118M | |
| Short-term investments · 2026-03-31 | $485M | |
| Accumulated deficit · 2026-03-31 | $-1.01B |
Risks flagged
Clinical-stage pre-revenue company with increasing cash burn
“Net loss increased to $158.3M in Q1 2026 from $45.6M in Q1 2025, while cash and investments decreased by $102.7M sequentially.”
29 Apr 20268-K · 2.02Cash and Securities $223M; R&D Expenses $14M; G&A Expenses $5Mearningsopen
Figures in the filing · each found in the filing text
| Cash and Securities · Q1-2026 | $223M | |
| R&D Expenses · Q1-2026 | $14M | |
| G&A Expenses · Q1-2026 | $5M | |
| Net Loss · Q1-2026 | $-18M |
Risks flagged
Clinical trial failure risk; no approved products; reliance on pipeline success.
“Clinical-stage biotech with no revenue; all programs in development.”
1 Apr 2026DEF 14AAnnual proxy statement filed for 2026 Annual Meeting, disclosing executive compensation, governance, and shareholder proposals.open
Figures in the filing · each found in the filing text
| Total Shareholder Return · FY2025 | 525.0% | |
| Net Loss · FY2025 | $-360M | |
| Common Shares Outstanding · 2026-03-20 | 115,893,943 | |
| CEO Base Salary · FY2026 | $740000.00 |
Risks flagged
Key Executive Departure
“On February 10, 2026, Ms. Mancini informed us that she will be retiring and therefore resigning from her role as our Chief Operating Officer, effective April 30, 2026.” · word for word
Pre-Revenue Stage
“At this time, given that we are a research and development company without revenue, we do not use any specific company-selected financial measures for purposes of determining 'Compensation Actually Paid.'” · word for word
Net Losses
“Net Loss ($ Millions) ... 2025 ... (359.6)”
11 Feb 202610-KResearch and Development Expenses $345M (+239% y/y); General and Administrative Expenses $48M (-2% y/y); Other Income, net $34M (-18% y/y)open
Figures in the filing · each found in the filing text
| Research and Development Expenses · FY2025 | $345M | +239% y/y |
| General and Administrative Expenses · FY2025 | $48M | -2% y/y |
| Other Income, net · FY2025 | $34M | -18% y/y |
| Federal Net Operating Loss Carryforwards · FY2025 | $195M | |
| State Net Operating Loss Carryforwards · FY2025 | $111M | |
| Foreign Net Operating Loss Carryforwards · FY2025 | $156M | |
| Stock Repurchase Authorization · FY2025 | $250M |
Risks flagged
Pre-revenue Stage with High Cash Burn
“We are a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders.”
Clinical Trial Failure Risk
“In addition, the stock market, in general, and small biopharmaceutical companies, in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies.” · word for word
Stock Price Volatility
“In addition, the stock market, in general, and small biopharmaceutical companies, in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies.” · word for word
Concentrated Ownership
“As of December 31, 2025, our executive officers, directors and 5% or greater stockholders beneficially owned 18.7% of our common stock.” · word for word
11 Feb 20268-K · 2.02Cash position $706Mearningsopen
Figures in the filing · each found in the filing text
| Cash position · 2025-12-31 | $706M |
Risks flagged
Phase 3 trials still ongoing; regulatory and commercial risks remain.
“Phase 3 VANQUISH trials ongoing; oral VK2735 Phase 3 in 3Q26”
Viking Therapeutics, Inc. — questions
- What did Viking Therapeutics, Inc. file recently?
- 9 SEC filings in the last 12 months. Latest: 8-K on 2026-09-28 — Viking Therapeutics completed equity and debt offerings: 2.00% Convertible Senior Notes due 2032; underwriting agreements with Morgan Stanley and J.P. Morgan.
Every figure on this page comes from Viking Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.